Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-Cells.
Animals
Biomimetic Materials
/ chemistry
Breast Neoplasms
/ pathology
CD4-Positive T-Lymphocytes
/ cytology
CD8-Positive T-Lymphocytes
/ cytology
Cell Line, Tumor
Cell Membrane
/ chemistry
Cell Movement
/ drug effects
Female
Fibroblasts
/ cytology
Humans
Hyaluronan Receptors
/ chemistry
Interferon-gamma
/ metabolism
Lung Neoplasms
/ pathology
Lymph Nodes
/ metabolism
Mice
Mice, Inbred BALB C
Nanoparticles
/ chemistry
Polylactic Acid-Polyglycolic Acid Copolymer
/ chemistry
Receptors, CXCR4
/ chemistry
cancer cell membrane biomimetic nanoparticles
cancer cell−fibroblast interaction
immune response
invasion
metastasis
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
27 Feb 2019
27 Feb 2019
Historique:
pubmed:
2
2
2019
medline:
19
7
2019
entrez:
2
2
2019
Statut:
ppublish
Résumé
Biomimetic nanoparticles (NPs) combine the flexibility and reproducibility of synthetic materials with the functionality of biological materials. Here, we developed and characterized biomimetic poly(lactic- co-glycolic acid) (PLGA) NPs coated with human cancer cell membrane fractions (CCMFs) to form CCMF-coated PLGA (CCMF-PLGA) NPs. We evaluated the ability of these CCMF-PLGA NPs to disrupt cancer cell-stromal cell interactions and to induce an immune response. Western blot analysis verified the plasma membrane purity of CCMFs. Confocal fluorescence microscopy and flow cytometry confirmed the presence of intact membrane-associated proteins including CXCR4 and CD44 following membrane derivation and coating. CCMFs and CCMF-PLGA NPs were capable of inhibiting cancer cell migration toward human mammary fibroblasts. Intravenous injection of CCMF-PLGA NPs significantly reduced experimental metastasis in vivo. Following immunization of Balb/c mice, near-infrared fluorescence imaging confirmed the migration of NPs to proximal draining lymph nodes (LNs). A higher percentage of CD8
Identifiants
pubmed: 30707559
doi: 10.1021/acsami.8b22309
pmc: PMC6628902
mid: NIHMS1037276
doi:
Substances chimiques
CD44 protein, human
0
CXCR4 protein, human
0
Hyaluronan Receptors
0
Receptors, CXCR4
0
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7850-7861Subventions
Organisme : NCI NIH HHS
ID : R35 CA209960
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA193365
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA136576
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM135457
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236616
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA198243
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA082337
Pays : United States
Références
J Biol Chem. 2000 Jun 23;275(25):19185-91
pubmed: 10764750
Eur J Pharmacol. 2000 Dec 8;409(2):143-54
pubmed: 11104827
Cancer Res. 1962 Jun;22:525-48
pubmed: 13858936
Nat Rev Cancer. 2009 Apr;9(4):285-93
pubmed: 19308068
Nat Protoc. 2009;4(11):1582-90
pubmed: 19816421
Cancer Res. 2010 May 15;70(10):3935-44
pubmed: 20460522
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5
pubmed: 21690347
J Control Release. 2012 Jul 20;161(2):505-22
pubmed: 22353619
Nanoscale. 2013 Apr 7;5(7):2664-8
pubmed: 23462967
Nat Nanotechnol. 2013 May;8(5):336-40
pubmed: 23584215
Nat Nanotechnol. 2013 Dec;8(12):933-8
pubmed: 24292514
Nanoscale. 2014 Mar 7;6(5):2730-7
pubmed: 24463706
Nano Lett. 2014;14(4):2181-8
pubmed: 24673373
Nucl Med Biol. 2014 Aug;41(7):552-61
pubmed: 25038987
Adv Healthc Mater. 2015 Aug 5;4(11):1645-52
pubmed: 25960053
Trends Biotechnol. 2015 Sep;33(9):514-524
pubmed: 26277289
Nature. 2015 Oct 1;526(7571):118-21
pubmed: 26374997
Int J Cancer. 2016 Mar 1;138(5):1207-19
pubmed: 26414794
Adv Mater. 2015 Nov 25;27(44):7043-50
pubmed: 26416431
Cancers (Basel). 2015 Dec 11;7(4):2443-58
pubmed: 26690480
Adv Mater. 2016 May;28(18):3460-6
pubmed: 26970518
Nanoscale. 2016 Apr 7;8(13):6981-5
pubmed: 26975904
ACS Appl Mater Interfaces. 2016 Apr 20;8(15):9610-8
pubmed: 27039688
Nanoscale. 2016 May 21;8(19):10364-70
pubmed: 27139582
ACS Nano. 2016 Aug 23;10(8):7738-48
pubmed: 27454827
Nano Lett. 2016 Sep 14;16(9):5895-901
pubmed: 27513184
Adv Mater. 2016 Nov;28(43):9573-9580
pubmed: 27626769
Adv Mater. 2016 Nov;28(43):9581-9588
pubmed: 27628433
Biomaterials. 2016 Dec;111:116-123
pubmed: 27728811
Bioconjug Chem. 2017 Jan 18;28(1):23-32
pubmed: 27798829
ACS Nano. 2016 Nov 22;10(11):10049-10057
pubmed: 27934074
ACS Nano. 2017 Feb 28;11(2):1397-1411
pubmed: 28075552
Adv Mater. 2017 Apr;29(16):
pubmed: 28199033
Biomaterials. 2017 Jun;128:69-83
pubmed: 28292726
ACS Nano. 2017 Jul 25;11(7):7006-7018
pubmed: 28665106
Biomaterials. 2017 Oct;142:149-161
pubmed: 28735175
Adv Mater. 2017 Dec;29(47):
pubmed: 29239517